Conditions: Neoplasm, Malignant
Keywords: Solid tumor malignancy sunitinib pemetrexed phase 1 neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Sunitinib, Pemetrexed intervention 2: Sunitinib, Pemetrexed
Intervention descriptions: intervention 1: Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity. intervention 2: Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.

Protocol document: